Press Releases

Vifor Fresenius Medical Care Renal Pharma  and Cara Therapeutics, Inc.  today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission’s final decision regarding marketing authorization for Kapruvia®. If approved, Kapruvia® will be the

New preclinical data demonstrated that tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), was the only BTK inhibitor with sufficient central nervous system (CNS) exposure and potency to modulate BTK signaling pathways within the CNS, as compared with evobrutinib and fenebrutinib. These results are being presented in a live poster presentation at the 7th annual Americas Committee for Treatment and Resea

Heidelberg Pharma AG and Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) today announced that the companies have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement. The agreements were concluded with wholly owned subsidiaries of Huadong, one of the leading pharmaceutical companies in China with a focus on oncology and ADC research, development and commercialization. The strategic part

Evoke Pharma, Inc.  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today announced that the results of a retrospective analysis of United States (US) administrative claims data that examined the association between tardive dyskinesia (TD) and potential risk factors will be presented at the annual Digestive Disease Week Meeting in San Diego, CA taking place from May 21-

TFF Pharmaceuticals, Inc.  a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the Company’s inhaled niclosamide product candidate completely inhibits viral replication of both the Delta and Omicron variants of SARS-CoV-2. Com

Cyclerion Therapeutics, Inc. and Ariana Pharma today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment. Ariana Pharma’s proprietary KEM® (Knowledge Extraction and Manageme

Global contract development and manufacturing organisation (CDMO), Recipharm, is investing to expand its sterile fill and finish production capabilities at its site in Monts, France. The manufacturing facility which specialises in the aseptic filling of pharmaceutical products, including biologics into vials and cartridges, currently has three lines for vials. The investment will expand Recipharm’s manufacturing footprint by adding a state-of-the-art, high-speed fill

Actinium Pharmaceuticals, Inc.  a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company, today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN). LibraTN is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of NOE-101 in adults with pain associated with TN. NOE-101 has previously been found to be safe an

Biotage helps shape the sustainable science of tomorrow and our future society for the benefit of humankind – HumanKind Unlimited. With this principle Biotage has set out a commitment to unleashing the potential of humanity by working tirelessly to improve the health and wellbeing of both our customers through greener and more efficient solutions, and our own employees through smarter working practices. As part of HumanKind Unlimited comes a commitment to sustainability at eve